Curated News
By: NewsRamp Editorial Staff
March 31, 2025
TAG1 Inc. to Join Expert Panel at Jones Las Vegas Technology Conference
TLDR
- TAG1 Inc. leads the way in cancer treatment with Lead-212 innovation, gaining a competitive edge in the radiopharmaceutical market.
- TAG1 Inc. will speak on radiopharma isotope roadmap at the Jones Conference, highlighting clinical & logistical aspects of Lead-212 supply chain.
- TAG1 Inc.'s participation at the Jones Conference contributes to advancing cancer treatment globally, ensuring next-gen therapies for patients in need.
- Join TAG1 Inc. at the Jones Las Vegas Tech & Innovation Conference to learn about the future of radiopharmaceuticals and cutting-edge medical advancements.
Impact - Why it Matters
This news highlights TAG1 Inc.'s role in advancing cancer treatment through innovative radioisotope technologies. Participation in the conference provides a platform for the company to showcase its progress, meet with investors, and contribute to discussions on the future of radiopharmaceuticals. The event underscores the importance of strengthening the supply chain for targeted alpha therapies to meet the growing clinical demand for critical isotopes.
Summary
TAG1 Inc., a radioisotope company specializing in Lead-212 for Targeted Alpha Therapies (TATs), will participate in the Jones Las Vegas Technology and Innovation Conference. CEO Sumit Verma will speak on a panel about radiopharmaceuticals alongside industry leaders from Lantheus Holdings and Radiopharm Theranostics. The event aims to facilitate direct dialogue between company executives and investors.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, TAG1 Inc. to Join Expert Panel at Jones Las Vegas Technology Conference
